

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Pharmaron Beijing Co., Ltd.*

康龍化成(北京)新藥技術股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3759)

**SUPPLEMENTAL ANNOUNCEMENT
CONTINUING CONNECTED TRANSACTIONS
COMMISSIONED EXPERIMENTS AND
RESEARCH FRAMEWORK AGREEMENT 2023**

Reference is made to the announcement of the Company dated October 29, 2023 in relation to the connected transaction contemplated under the Framework Agreement 2023 (the “**Announcement**”). Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Announcement. In addition to the information disclosed in the Announcement, the Company would like to provide further details regarding the payment terms stipulated under the Framework Agreement 2023 and information on the shareholders of Newbay Group.

Payment terms

Relevant member(s) of the Group and the relevant member(s) of the Newbay Group will from time to time enter into separate individual agreement(s) or work order(s), which shall set out the specific terms and conditions, including service scope, service fees, payment arrangements and other terms, subject to and in accordance with the Framework Agreement 2023. In addition to the Group’s internal control policies set out in the Announcement, both of the finance department and the business development department of the Group will review the pricing terms and payment arrangements of such separate individual agreement(s) or work order(s), and will compare such terms with those offered to other independent third party customers for similar services prior to entering into such separate agreement(s) or work order(s), to ensure that the transactions are on normal commercial terms, and that the terms thereunder are fair, reasonable and consistent with the terms offered to other independent third party customers for similar services.

Information on the shareholders of Newbay Group

Ningbo Xinwantaixin was established for the purpose of incentivizing employees of Newbay Technology, and is currently held as to 99% and 1% by Mr. Shen Zhenhai (as a general partner) and Ms. Yuan Mingyuan (as a general partner), being the employees of Newbay Technology who are Independent Third Parties.

Ningbo Yingxin is held as to 30.7586%, 19.2476%, 19.2476%, 15.3731% and 15.3731% by Mr. Yu Yuejiang (as a general partner), Mr. Yu Jian (as a limited partner), Mr. Hua Changyong (as a limited partner), Mr. Du Guoqiang (as a limited partner) and Mr. Cen Zhongda (as a limited partner), who are all Independent Third Parties.

Five Group Holdings Limited is a limited company incorporated in Hong Kong and is owned as to 100% by Highlight Capital Partners I L.P. (“**Highlight Capital**”), an exempted limited partnership formed under the laws of the Cayman Islands. Highland Capital is ultimately controlled by Mr. Stephen Hui Wang, who is an Independent Third Party.

Saved as disclosed above, all other information as set out in the Announcement remains unchanged and shall continue to be valid for all purposes. This announcement is supplemental to and should be read in conjunction with the Announcement.

By order of the Board
Pharmaron Beijing Co., Ltd.*
康龍化成(北京)新藥技術股份有限公司
Dr. Lou Boliang
Chairman

Beijing, the PRC
November 6, 2023

As at the date of this announcement, the Board of Directors comprises Dr. Lou Boliang, Mr. Lou Xiaoqiang and Ms. Zheng Bei as executive Directors; Mr. Hu Baifeng and Mr. Li Jiaqing as non-executive Directors; Ms. Li Lihua, Mr. Zhou Qilin, Mr. Tsang Kwan Hung Benson and Mr. Yu Jian as independent non-executive Directors.

* For identification purposes only